Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40744-024-00740-8 | DOI Listing |
Publication Analysis
Top Keywords
letter editor
4
editor "geographical
4
"geographical differences
4
differences safety
4
safety efficacy
4
efficacy tofacitinib
4
tofacitinib versus
4
versus tnfi
4
tnfi post
4
post hoc
4
Similar Publications
Response to Letter to Editor.
Pediatr Radiol
January 2025
Department of Radiology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR, 72205, USA.
Letter-to-the-editor to the study by Bartek J "Multidisciplinary consensus-based statement on the current role of Middle Meningeal Artery embolization (MMAE) in chronic SubDural Hematoma (cSDH)" - A letter from the international CSDH research group committee, iCORIC.
Brain Spine
December 2024
Department of Neurosurgery, South West Neurosurgical Centre, Plymouth, United Kingdom.
Letter to the Editor From Papadimitriou: "Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes".
J Clin Endocrinol Metab
January 2025
Department of Pediatrics, University General Hospital of Larisa, Mezourlo, Larisa 41334, Greece.
Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
Rheumatol Ther
January 2025
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
A Response to: Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
Rheumatol Ther
January 2025
Pfizer SLU, Madrid, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!